Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2018 - 2026)

Mirum Pharmaceuticals' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $324.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 53.39% year-over-year to $324.9 million in Q1 2026; TTM through Mar 2026 was $324.9 million, a 53.39% increase from a year earlier, with the FY2025 full-year figure at $296.7 million, up 33.08% from the prior year.
• Cash & Equivalents advanced to $324.9 million in Q1 2026 per MIRM's latest filing, from $296.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $324.9 million in Q1 2026 and bottomed at $480000.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $228.1 million (2025), against an average of $215.6 million.
• Across the five-year window, Cash & Equivalents surged 512.81% in 2024 and plunged 99.78% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $128.0 million in 2022, then soared by 123.69% to $286.3 million in 2023, then decreased by 22.14% to $222.9 million in 2024, then surged by 33.08% to $296.7 million in 2025, then climbed by 9.51% to $324.9 million in 2026.
• Per Business Quant, the three latest MIRM Cash & Equivalents figures stand at $324.9 million (Q1 2026), $296.7 million (Q4 2025), and $480000.0 (Q3 2025).